Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Disease × Diagnosis, Computer-Assisted × Clear all

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Conditions

Melanoma 1 Disease 1

Interventions

fluciclovine F-18 2 Positron-Emission Tomography 2 Injections 2 Dexamethasone 2 tislelizumab 1 ricolinostat 1 pomalidomide 1 pembrolizumab 1 gossypol acetic acid 1 daratumumab 1 aflibercept 1 Prednisone 1 Oncolytic Virotherapy 1 Octreotide 1 Mitomycin 1 Mammography 1 Lenalidomide 1 Ipilimumab 1 Drug Delivery Systems 1 Docetaxel 1 Diagnosis, Computer-Assisted 1 Daunorubicin 1 Cytarabine 1 Control Groups 1 CPX-351 1 Bevacizumab 1 Antibodies, Monoclonal 1 3-Iodobenzylguanidine 1 3-(1-benzenesulfonyl-2,3-dihydro-1H-indol-5-yl)-N-hydroxyacrylamide 1 2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06221397 2026-03-16

LEGIT_MC_EVCDA

AI Labs Group S.L

105 enrolled 15 charts

Disease, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡